JAZZ
VENTE TOTALE: 12 000 titres (~3 018 660,00 $ US)
- Insiders
- COZADD BRUCE C
- Total bought
- —
- Total sold
- $3,018,660
- Last activity
- 2026-09-01
- Last synced
-
2026-09-07 10:23:47
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-04
JAZZ presents a deeply stressed balance sheet with a debt-to-EBITDA of 37.18x, near-zero debt service coverage (0.31x), and a transition to net losses, making the financial foundation too fragile to support an…
The first sentence of the analysis written for JAZZ on 2026-09-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 88.2% | 89.0% | 88.6% | 85.2% | 85.8% | |
| Ebit Margin | -10.2% | 21.2% | 21.1% | 22.9% | 15.4% | |
| Ebitda Margin | 2.5% | 37.4% | 37.8% | 40.1% | 33.2% | |
| Operating Profit Margin | 5.3% | 17.6% | 15.1% | -1.8% | 5.5% | |
| Pretax Profit Margin | -14.7% | 11.5% | 7.7% | -10.5% | -3.7% | |
| Continuous Operations Profit Margin | -8.3% | 13.8% | 10.8% | -6.1% | -10.7% | |
| Net Profit Margin | -8.3% | 13.8% | 10.8% | -6.1% | -10.6% | |
| Bottom Line Profit Margin | -8.3% | 14.0% | 11.5% | -6.1% | -10.7% | |
| Current Ratio | 1.858 | 4.457 | 2.236 | 2.793 | 3.227 | |
| Quick Ratio | 1.672 | 3.995 | 1.847 | 2.028 | 1.901 | |
| Solvency Ratio | 0.025 | 0.154 | 0.138 | 0.052 | 0.027 | |
| Cash Ratio | 0.621 | 2.323 | 0.980 | 0.945 | 0.731 | |
| Price To Earnings Ratio | -29.110 | 13.593 | 18.779 | -44.500 | -23.122 | |
| Price To Earnings Growth Ratio | 0.177 | 0.355 | -0.066 | 1.270 | 0.101 | |
| Forward Price To Earnings Growth Ratio | 0.177 | 0.355 | -0.066 | 1.270 | 0.101 | |
| Price To Earnings Diluted Ratio | -29.110 | 14.237 | 20.164 | -44.500 | -23.122 | |
| Price To Earnings Diluted Growth Ratio | 0.174 | 0.341 | -0.075 | 1.270 | 0.100 | |
| Price To Book Ratio | 2.401 | 1.860 | 2.083 | 3.229 | 1.918 | |
| Price To Sales Ratio | 2.429 | 1.872 | 2.030 | 2.723 | 2.458 | |
| Price To Free Cash Flow Ratio | 9.046 | 5.650 | 7.289 | 12.876 | 10.376 | |
| Price To Operating Cash Flow Ratio | 7.647 | 5.455 | 7.129 | 7.833 | 9.769 | |
| Debt To Assets Ratio | 0.465 | 0.513 | 0.508 | 0.536 | 0.500 | |
| Debt To Equity Ratio | 1.256 | 1.505 | 1.550 | 1.884 | 1.552 | |
| Debt To Capital Ratio | 0.557 | 0.601 | 0.608 | 0.653 | 0.608 | |
| Long Term Debt To Capital Ratio | 0.501 | 0.598 | 0.578 | 0.649 | 0.603 | |
| Financial Leverage Ratio | 2.700 | 2.934 | 3.049 | 3.511 | 3.102 | |
| Working Capital Turnover Ratio | 1.548 | 1.483 | 2.147 | 2.106 | 1.552 | |
| Operating Cash Flow Ratio | 0.605 | 1.344 | 0.711 | 1.363 | 0.962 | |
| Operating Cash Flow Sales Ratio | 0.318 | 0.343 | 0.285 | 0.348 | 0.252 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.845 | 0.966 | 0.978 | 0.608 | 0.942 | |
| Debt Service Coverage Ratio | 0.311 | 5.995 | 1.755 | 5.097 | 2.620 | |
| Interest Coverage Ratio | 1.151 | 3.010 | 1.999 | -0.227 | 0.611 | |
| Short Term Operating Cash Flow Coverage Ratio | 1.316 | 45.029 | 1.805 | 41.032 | 25.113 | |
| Operating Cash Flow Coverage Ratio | 0.250 | 0.227 | 0.189 | 0.219 | 0.127 | |
| Capital Expenditure Coverage Ratio | 6.464 | 29.039 | 45.572 | 2.553 | 17.098 | |
| Dividend Paid And Capex Coverage Ratio | 6.464 | 29.039 | 45.572 | 2.553 | 17.098 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 132.761 | 7.468 | 8.328 | 10.141 | 12.811 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 88.2% | ▼-0.8% | ▲0.8% |
| Ebit Margin | -10.2% | ▼-31.3% | ▼-24.2% |
| Ebitda Margin | 2.5% | ▼-34.9% | ▼-27.7% |
| Operating Profit Margin | 5.3% | ▼-12.3% | ▼-3.1% |
| Pretax Profit Margin | -14.7% | ▼-26.2% | ▼-12.8% |
| Continuous Operations Profit Margin | -8.3% | ▼-22.1% | ▼-8.2% |
| Net Profit Margin | -8.3% | ▼-22.1% | ▼-8.2% |
| Bottom Line Profit Margin | -8.3% | ▼-22.4% | ▼-8.4% |
| Current Ratio | 1.858 | ▼-2.599 | ▼-1.056 |
| Quick Ratio | 1.672 | ▼-2.323 | ▼-0.617 |
| Solvency Ratio | 0.025 | ▼-0.129 | ▼-0.054 |
| Cash Ratio | 0.621 | ▼-1.703 | ▼-0.499 |
| Price To Earnings Ratio | -29.110 | ▼-42.702 | ▼-16.238 |
| Price To Earnings Growth Ratio | 0.177 | ▼-0.178 | ▼-0.190 |
| Forward Price To Earnings Growth Ratio | 0.177 | ▼-0.178 | ▼-0.190 |
| Price To Earnings Diluted Ratio | -29.110 | ▼-43.347 | ▼-16.643 |
| Price To Earnings Diluted Growth Ratio | 0.174 | ▼-0.167 | ▼-0.188 |
| Price To Book Ratio | 2.401 | ▲0.540 | ▲0.102 |
| Price To Sales Ratio | 2.429 | ▲0.558 | ▲0.127 |
| Price To Free Cash Flow Ratio | 9.046 | ▲3.396 | ▼-0.001 |
| Price To Operating Cash Flow Ratio | 7.647 | ▲2.191 | ▲0.080 |
| Debt To Assets Ratio | 0.465 | ▼-0.048 | ▼-0.040 |
| Debt To Equity Ratio | 1.256 | ▼-0.249 | ▼-0.293 |
| Debt To Capital Ratio | 0.557 | ▼-0.044 | ▼-0.049 |
| Long Term Debt To Capital Ratio | 0.501 | ▼-0.097 | ▼-0.085 |
| Financial Leverage Ratio | 2.700 | ▼-0.234 | ▼-0.359 |
| Working Capital Turnover Ratio | 1.548 | ▲0.065 | ▼-0.219 |
| Operating Cash Flow Ratio | 0.605 | ▼-0.740 | ▼-0.392 |
| Operating Cash Flow Sales Ratio | 0.318 | ▼-0.025 | ▲0.009 |
| Free Cash Flow Operating Cash Flow Ratio | 0.845 | ▼-0.120 | ▼-0.022 |
| Debt Service Coverage Ratio | 0.311 | ▼-5.684 | ▼-2.845 |
| Interest Coverage Ratio | 1.151 | ▼-1.859 | ▼-0.158 |
| Short Term Operating Cash Flow Coverage Ratio | 1.316 | ▼-43.713 | ▼-21.543 |
| Operating Cash Flow Coverage Ratio | 0.250 | ▲0.023 | ▲0.048 |
| Capital Expenditure Coverage Ratio | 6.464 | ▼-22.575 | ▼-13.682 |
| Dividend Paid And Capex Coverage Ratio | 6.464 | ▼-22.575 | ▼-13.682 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 132.761 | ▲125.293 | ▲98.459 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $10.37B | $7.62B | $7.78B | $9.96B | $7.61B | |
| Enterprise value | $14.40B | $11.36B | $12.07B | $14.89B | $13.17B | |
| EV / Sales | 3.37x | 2.79x | 3.15x | 4.07x | 4.25x | |
| EV / Op. cash flow | 10.62x | 8.14x | 11.05x | 11.71x | 16.91x | |
| EV / Free cash flow | 12.56x | 8.43x | 11.30x | 19.25x | 17.96x | |
| EV / EBITDA | 132.76x | 7.47x | 8.33x | 10.14x | 12.81x | |
| Net debt / EBITDA | 37.17x | 2.46x | 2.96x | 3.36x | 5.41x | |
| Current ratio | 1.86x | 4.46x | 2.24x | 2.79x | 3.23x | |
| Income quality | -3.81x | 2.49x | 2.63x | -5.68x | -2.36x | |
| Graham number | — | $116 | $93 | — | — | |
| Graham net-net | -$67 | -$67 | -$82 | -$96 | -$114 | |
| Tax burden | 56.7% | 119.5% | 140.7% | 58.5% | 289.7% | |
| Interest burden | 145.0% | 54.4% | 36.4% | -45.6% | -23.9% | |
| Working capital | $1.92B | $3.59B | $1.90B | $1.67B | $1.80B | |
| Invested capital | $8.44B | $10.29B | $9.30B | $9.46B | $11.13B | |
| Return on assets | -3.1% | 4.7% | 3.6% | -2.1% | -2.7% | |
| Operating ROA | 1.9% | 6.1% | 5.2% | -0.6% | 1.8% | |
| Return on tangible assets | -6.6% | 10.1% | 9.8% | -6.7% | -9.9% | |
| Return on equity | -8.2% | 13.7% | 11.1% | -7.3% | -8.3% | |
| Return on invested capital | 1.2% | 6.5% | 5.5% | -0.4% | 1.5% | |
| Return on capital employed | 2.4% | 6.5% | 5.9% | -0.7% | 1.5% | |
| Earnings yield | -3.4% | 7.4% | 5.3% | -2.2% | -4.3% | |
| Free cash flow yield | 11.1% | 17.7% | 13.7% | 7.8% | 9.6% | |
| Capex / Op. cash flow | 15.5% | 3.4% | 2.2% | 39.2% | 5.8% | |
| Capex / Depreciation | 30.1% | 7.3% | 3.8% | 79.1% | 8.2% | |
| Capex / Sales | 4.9% | 1.2% | 0.6% | 13.6% | 1.5% | |
| SG&A / Sales | 42.4% | 34.0% | 35.0% | 38.7% | 46.9% | |
| R&D / Sales | 18.3% | 21.7% | 22.2% | 16.1% | 16.3% | |
| Stock comp / Sales | 6.8% | 6.1% | 5.9% | 6.1% | 6.1% | |
| Intangibles / Total assets | 53.7% | 53.9% | 62.9% | 69.1% | 73.0% | |
| Days sales outstanding | 71d | 64d | 67d | 65d | 66d | |
| Days payables outstanding | 89d | 64d | 86d | 61d | 83d | |
| Operating cycle | 373d | 458d | 567d | 547d | 955d | |
| Cash conversion cycle | 285d | 394d | 481d | 486d | 872d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+36.1%EV / Sales ▲+20.8%EV / EBITDA ▲+1677.6%EV / Op. cash flow ▲+2.479Earnings yield ▼-0.108
Profitability
Return on equity ▼-0.219Return on assets ▼-0.077Return on invested capital ▼-0.053Return on capital employed ▼-0.041Operating ROA ▼-0.042Income quality ▼-6.299Tax burden ▼-0.628
Efficiency
Days sales outstanding ▲+6.756Days payables outstanding ▲+24.753Operating cycle ▼-84.298Cash conversion cycle ▼-109.051Capex / Sales ▲+0.037R&D / Sales ▼-0.034
Balance-sheet strength
Current ratio ▼-2.599Net debt / EBITDA ▲+34.711Working capital ▼-1666933001.000Invested capital ▼-1848359001.000Intangibles / Total assets ▼-0.002
Change over 5 years
Valuation
Market cap ▲+36.3%EV / Sales ▼-20.7%EV / EBITDA ▲+936.3%EV / Op. cash flow ▼-6.292Earnings yield ▲+0.009
Profitability
Return on equity +0.000Return on assets ▼-0.004Return on invested capital ▼-0.003Return on capital employed ▲+0.009Operating ROA ▲+0.001Income quality ▼-1.445Tax burden ▼-2.330
Efficiency
Days sales outstanding ▲+4.598Days payables outstanding ▲+5.463Operating cycle ▼-581.350Cash conversion cycle ▼-586.812Capex / Sales ▲+0.034R&D / Sales ▲+0.020
Balance-sheet strength
Current ratio ▼-1.369Net debt / EBITDA ▲+31.763Working capital ▲+121490999.000Invested capital ▼-2684282001.000Intangibles / Total assets ▼-0.193
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2023-07-12 | Daniel Goldman | Sale | $15,001 - $50,000 |
| 2023-05-19 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Purchase | $15,001 - $50,000 |
| 2023-01-31 | Daniel Goldman | Sale | $1,001 - $15,000 |
| 2022-09-26 | Thomas Suozzi | Sale (Full) | $1,001 - $15,000 |
| 2021-10-19 | Thomas Suozzi | Purchase | $1,001 - $15,000 |
| 2019-07-15 | Bill Flores | Purchase | $15,001 - $50,000 |
Recent news
- 2026-09-02 Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences DUBLIN, Sept. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 1:30 p.m.
- 2026-09-02 Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report? Jazz (JAZZ) reported earnings 30 days ago. What''s next for the stock?
- 2026-09-01 JAZZ Rises on Updated OS Results From Gastric Cancer Study Jazz up as updated HERIZON-GEA-01 results show statistically significant OS benefits for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma.
- 2026-08-31 Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA HERIZON-GEA-01 results reinforce recently FDA-approved Ziihera as the definitive HER2-targeted backbone therapy in first-line GEA Longer follow up of Ziihera plus tislelizumab and chemotherapy shows improved OS hazard ratio, further supporting this regimen as the new standard of care Data submitted for presentation in fourth quarter 2026 For U.S. media and investors only DUBLIN, Aug. 31, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced second interim top-line overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial showing that Ziihera® (zanidatamab-hrii) in combination with chemotherapy demonstrated statistically significant and clinically meaningful improvements in OS compared with trastuzumab plus chemotherapy as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The Ziihera plus chemotherapy OS hazard ratio improved compared with the first interim analysis.
- 2026-08-27 Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA Jazz Pharmaceuticals (NASDAQ: JAZZ) outlined its plans for the U.S. launch of Ziihera following FDA approval of the therapy for first-line HER2-positive unresectable, locally advanced or metastatic gastroesophageal adenocarcinoma, or GEA. Ziihera, or zanidatamab, is approved in combination with tislelizumab and fluoropyrimidine- and platinum-containing chemotherapy for patients whose tumors are HER2 IHC 3+ or IHC 2+
- 2026-08-27 Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previously announced offering size of $1.0 billion aggregate principal amount of notes.
- 2026-08-26 JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer Jazz Pharmaceuticals'' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.
- 2026-08-26 These Analysts Increase Their Forecasts On Jazz Pharmaceuticals The U.S. Food and Drug Administration (FDA), on Tuesday, approved Jazz Pharmaceuticals plc''s (NASDAQ:JAZZ) two Ziihera-containing combination regimens as first-line treatments for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.
- 2026-08-26 Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases DUBLIN, Aug. 26, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Issuer also intends to grant the initial purchasers of the notes the right to purchase, exercisable within a 13-day period from, and including the initial issue date of the notes, up to an additional $150.0 million aggregate principal amount of notes.
- 2026-08-25 Jazz Pharmaceuticals plc (JAZZ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Line HER2-Positive GEA Transcript Jazz Pharmaceuticals plc (JAZZ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Line HER2-Positive GEA Transcript